Literature DB >> 10490933

Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.

S Ekins1, G Bravi, J H Wikel, S A Wrighton.   

Abstract

To gain a better understanding of the active site of cytochrome P-450 (CYP) 3A4, a three-dimensional-quantitative structure activity relationship model was constructed using the structures and K(m (apparent)) values of 38 substrates of human liver microsomal CYP3A4. This pharmacophore was built using the program Catalyst and consisted of four features: two hydrogen bond acceptors, one hydrogen bond donor, and one hydrophobic region. The pharmacophore demonstrated a fit value (r) of observed and expected K(m(apparent)) value of 0.67. The validity of the CYP3A4 substrate model was tested by twice permuting (randomizing) the activity values and substrate structures. The results of this validation procedure indicated that the original model was a significant representation of the features required of CYP3A4 substrates. The second validation method used the Catalyst model to predict the K(m(apparent)) values of a test set of structurally diverse substrates for CYP3A4 not included in the 38 molecules used to build the model. Two fitting algorithms included in this software were examined: fast fit and best fit. The fast fitting method resulted in predictions for all 12 substrates that were within 1 log unit for the residual [i.e., the difference between predicted and observed K(m(apparent))]. In contrast, the best fit algorithm poorly predicted the K(m (apparent)) values (i.e., residual >1 log unit) of 4 of 12 substrates. These poor fits with the best fit function suggest that the fast fit method within Catalyst is more representative of the observed K(m(apparent)) values for CYP3A4 substrates and enables good in silico prediction of this activity. A Catalyst common features pharmacophore was also constructed from three molecules known to activate their own metabolism included in the 38 molecules of the initial CYP3A4 model. This demonstrated that activators of CYP3A4 possess multiple hydrophobic regions that might correspond with a region in the active site away from the metabolic site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490933

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism.

Authors:  G M Keseru
Journal:  J Comput Aided Mol Des       Date:  2001-07       Impact factor: 3.686

2.  Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Authors:  Zongling Xia; Mingli Wang; Sulan Zou; Rong Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 2.441

Review 3.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

5.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

Review 6.  Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.

Authors:  E J Reschly; Matthew D Krasowski
Journal:  Curr Drug Metab       Date:  2006-05       Impact factor: 3.731

7.  Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.

Authors:  Noelia Nebot; Severine Crettol; Fabrizio d'Esposito; Bruce Tattam; David E Hibbs; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 8.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

9.  Towards a new age of virtual ADME/TOX and multidimensional drug discovery.

Authors:  Sean Ekins; Bruno Boulanger; Peter W Swaan; Maggie A Z Hupcey
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

10.  Pharmacophore mapping of arylamino-substituted benzo[b]thiophenes as free radical scavengers.

Authors:  Indrani Mitra; Achintya Saha; Kunal Roy
Journal:  J Mol Model       Date:  2010-03-01       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.